{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:43:53Z","timestamp":1772851433872,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jacl.2019.10.004","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T12:40:18Z","timestamp":1571056818000},"page":"979-988.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150\u00a0mg doses"],"prefix":"10.1016","volume":"13","author":[{"given":"Jennifer G.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli M.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marja-Riitta","family":"Taskinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen M.","family":"Colhoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelie","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Thomas","family":"DiCioccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Lecorps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Pordy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie T.","family":"Baccara-Dinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2019.10.004_bib1","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2019.10.004_bib2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cca.2014.07.008","article-title":"PCSK9 and lipid lowering drugs","volume":"437","author":"Guo","year":"2014","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jacl.2019.10.004_bib3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jacl.2015.01.001","article-title":"Understanding PCSK9 and anti-PCSK9 therapies","volume":"9","author":"McKenney","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2019.10.004_bib4","doi-asserted-by":"crossref","first-page":"e003323","DOI":"10.1161\/JAHA.116.003323","article-title":"Relationship between low-density lipoprotein cholesterol, free proprotein convertase subtilisin\/kexin type 9, and alirocumab levels after different lipid-lowering strategies","volume":"5","author":"Rey","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2019.10.004_bib5","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2019.10.004_bib6","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2019.10.004_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2019.10.004_bib8","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2019.10.004_bib9","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2019.10.004_bib10","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2019.10.004_bib11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","article-title":"Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial","volume":"8","author":"Moriarty","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2019.10.004_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dl or higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2019.10.004_bib13","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial","volume":"100","author":"Bays","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2019.10.004_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","article-title":"Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial","volume":"244","author":"Farnier","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.10.004_bib15","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2019.10.004_bib16","doi-asserted-by":"crossref","first-page":"e003421","DOI":"10.1161\/JAHA.116.003421","article-title":"Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study","volume":"5","author":"Stroes","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2019.10.004_bib17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.atherosclerosis.2016.08.043","article-title":"A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I","volume":"254","author":"Roth","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.10.004_bib18","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ijcard.2016.08.273","article-title":"Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials","volume":"223","author":"Farnier","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2019.10.004_bib19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/MCA.0000000000000438","article-title":"Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia","volume":"28","author":"Kastelein","year":"2017","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.jacl.2019.10.004_bib20","doi-asserted-by":"crossref","first-page":"e000028","DOI":"10.1161\/JAHA.112.000028","article-title":"Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy","volume":"2","author":"Raal","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2019.10.004_bib21","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/M17-2485","article-title":"Diagnosing resistance to a proprotein convertase Subtilisin\/Kexin type 9 inhibitor","volume":"168","author":"Shapiro","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2019.10.004_bib22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10557-018-6784-z","article-title":"Assessment of the 1% of patients with consistent <15% reduction in low-density lipoprotein cholesterol: pooled analysis of 10 phase 3 ODYSSEY alirocumab trials","volume":"32","author":"Bays","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2019.10.004_bib23","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacl.2017.12.008","article-title":"Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia","volume":"12","author":"Hartgers","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2019.10.004_bib24","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.amjcard.2016.08.072","article-title":"Safety of alirocumab (a PCSK9 monoclonal antibody) from 14 randomized trials","volume":"118","author":"Jones","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2019.10.004_bib25","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287419302880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287419302880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:35:51Z","timestamp":1761831351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287419302880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1933287419302880"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2019.10.004","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150\u00a0mg doses","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2019.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}